Senores Pharmaceuticals Q2FY27 Results and Joint Statutory Auditor Appointment
Senores Pharmaceuticals Ltd · Change in Auditor · 29 Oct 2026, 7:39 pm
Senores Pharmaceuticals Q2FY27 Results and Joint Statutory Auditor Appointment Senores Pharmaceuticals reported consolidated Q2FY27 revenue of ₹192.33 crore, up 24.9% YoY, with EBITDA surging 38% YoY to ₹58 crore and PAT rising 21.5% YoY to ₹36.60 crore. For H1FY27, revenue climbed 30.0% YoY to ₹372.54 crore, while PAT reached ₹67.05 crore, up 30.7% YoY. Operating cash flow improved to ₹29.22 crore in H1FY27. Management guided for 30–40% revenue growth and 50–60% PAT growth in FY27. Additionally, the board approved appointing M/s Talati and Talati LLP as Joint Statutory Auditors for FY27–FY31.
Original exchange filing (PDF)
More announcements from Senores Pharmaceuticals Ltd
- We are pleased to announce that the manufacturing facility of our Subsidiary Company., Ratnatris Pharmaceuticals Private Limited has been awarded with the prestigious PIC/S GMP certification .... · 18 Nov 2026
- Senores Pharmaceuticals Limited has informed the exchange regarding transcript of earnings conference call held on October 29, 2026 · 05 Nov 2026
- Senores Pharmaceuticals Limited has informed the exchange regarding audio recording of earnings conference call for quarter ended September 30, 2026 · 30 Oct 2026
- Senores Pharmaceuticals Limited has informed the exchange regarding submission of statement of deviation or variation in utilisation of funds raised through preferential issue of convertible .... · 29 Oct 2026
- Senores Pharmaceuticals Limited has informed the exchange regarding submission of statement of deviation or variation in utilisation of funds of public issue for quarter ended on September 30, 2026 · 29 Oct 2026
- Senores Pharmaceuticals Limited has informed the exchange regarding Monitoring Agency report for the quarter ended September 30, 2026 · 29 Oct 2026
- We enclose herewith the Investor Presentation for Q2 & H1FY27 · 29 Oct 2026
- Senores Pharmaceuticals Limited has informed the exchange regarding media release · 29 Oct 2026
